255 related articles for article (PubMed ID: 25658613)
1. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
[TBL] [Abstract][Full Text] [Related]
2. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.
Tareen SU; Kelley-Clarke B; Nicolai CJ; Cassiano LA; Nelson LT; Slough MM; Vin CD; Odegard JM; Sloan DD; Van Hoeven N; Allen JM; Dubensky TW; Robbins SH
Mol Ther; 2014 Mar; 22(3):575-587. PubMed ID: 24419083
[TBL] [Abstract][Full Text] [Related]
3. Engineered lentivector targeting of dendritic cells for in vivo immunization.
Yang L; Yang H; Rideout K; Cho T; Joo KI; Ziegler L; Elliot A; Walls A; Yu D; Baltimore D; Wang P
Nat Biotechnol; 2008 Mar; 26(3):326-34. PubMed ID: 18297056
[TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
5. Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo.
Daenthanasanmak A; Salguero G; Borchers S; Figueiredo C; Jacobs R; Sundarasetty BS; Schneider A; Schambach A; Eiz-Vesper B; Blasczyk R; Weissinger EM; Ganser A; Stripecke R
Vaccine; 2012 Jul; 30(34):5118-31. PubMed ID: 22691433
[TBL] [Abstract][Full Text] [Related]
6. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
7. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.
Tenbusch M; Nchinda G; Storcksdieck genannt Bonsmann M; Temchura V; Überla K
Int Immunol; 2013 Apr; 25(4):247-58. PubMed ID: 23184617
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
[TBL] [Abstract][Full Text] [Related]
9. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.
Goold HD; Escors D; Conlan TJ; Chakraverty R; Bennett CL
J Immunol; 2011 Apr; 186(8):4565-72. PubMed ID: 21389256
[TBL] [Abstract][Full Text] [Related]
10. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
Song W; Kong HL; Carpenter H; Torii H; Granstein R; Rafii S; Moore MA; Crystal RG
J Exp Med; 1997 Oct; 186(8):1247-56. PubMed ID: 9334364
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
13. An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.
Ma S; Chen X; Tan Q; Li D; Dai S; Wu S; Yu Y; Zang G; Tang Z
Cell Cycle; 2018; 17(10):1220-1234. PubMed ID: 30019620
[TBL] [Abstract][Full Text] [Related]
14. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
Mossoba ME; Walia JS; Rasaiah VI; Buxhoeveden N; Head R; Ying C; Foley JE; Bramson JL; Fowler DH; Medin JA
Mol Ther; 2008 Mar; 16(3):607-17. PubMed ID: 18180774
[TBL] [Abstract][Full Text] [Related]
15. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
[TBL] [Abstract][Full Text] [Related]
16. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Bryson PD; Han X; Truong N; Wang P
Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
[TBL] [Abstract][Full Text] [Related]
18. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
19. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
[TBL] [Abstract][Full Text] [Related]
20. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
